CardioSen’CTM receives FDA clearance

World’s first wireless 12 Lead Digital Cellular personal ECG
transmitter CardioSen’CTM receives FDA clearance.

The US Food and Drug administration (FDA) cleared SHL Telemedicine’s CardioSen’CTM, the world’s first personal cellular-digital 12-lead ECG transmitter used for the purpose of remote real-time diagnosis of arrhythmia, ischemia, and myocardial infarction to medical call centers.

The CardioSen’CTM is to be used for the purpose of remote real-time diagnosis of arrhythmia, ischemia, and myocardial infarction. The ECG is then analyzed by the medical professionals at the medical call center. Together with a clinical description given by the patient it provides the medical professionals with the data needed to diagnose the situation and provide medical assistance, if necessary. The CardioSen’CTM is being used in Israel since the middle of 2007
and has been very well accepted by SHL subscribers.

This innovative portable device significantly simplifies the measurement and transmission of a 12-lead ECG and rhythm strip in real-time due to its ergonomic design, compact dimensions, lightweight, vocal prompts and remote operation capabilities by the medical call center personnel.

In addition to the ease and simplicity of use the CardioSen’CTM enables transmission with maximal accuracy and speed due to the use of a built in cellular modem.

“We are very pleased to have gained FDA approval for the CardioSen’CTM “, comments Erez Alroy, Co-CEO of SHL Telemedicine. “Today, a third of all heart attacks end fatally. Our CardioSen’CTM can help to drastically reduce morbidity and mortality rates in such incidents while significantly simplifying the procedure for patients at the same time. We are looking forward to bringing this device to the markets”, he continues.

Other SHL-brand FDA-approved heart care devices include the CardioBeeperTM, CardioBeeper 12LTM and the CardioPocketTM. Further information on the CardioSen’CTM and other products are available at

Download Press Release